December 15, 2024 18:00 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Kolkata woman strangled, beheaded and chopped into pieces for refusing brother-in-law's advances | Arvind Kejriwal, CM Atishi to contest Delhi polls from current constituencies | Atul Subhash suicide case: Wife Nikita, her mother and brother arrested | Pushpa 2 stampede: Allu Arjun walks out of jail, actor's lawyer slams delay in release | Donald Trump intends to end 'inconvenient' and 'very costly' Daylight Saving Time | Suchir Balaji: Indian-origin former OpenAI researcher found dead at US apartment | Bengaluru techie suicide: Karnataka Police issues summons to wife Nikita, her family members | French President Macron appoints centrist leader Francois Bayrou as new Prime Minister | Congress always prioritised personal interest over Constitution: Rajnath Singh | Jaishankar calls attack on Hindus in Bangladesh 'a source of concern'
Glenmark introduces higher strength FabiFlu to reduce pill burden of COVID-19 treatment

Glenmark introduces higher strength FabiFlu to reduce pill burden of COVID-19 treatment

Aug 06, 2020, at 10:31 pm

Mumbai/UNI: Pharma major Glenmark announced on Thursday that it has introduced a 400 mg version of oral antiviral FabiFlu, for treating mild to moderate COVID-19 in India.

Glenmark slashes price of COVID-19 drug FabiFlu to Rs. 75 per tablet

Glenmark slashes price of COVID-19 drug FabiFlu to Rs. 75 per tablet

Jul 13, 2020, at 11:52 pm

Mumbai:  Glenmark Pharmaceuticals, a research-led, integrated global pharmaceuticalcompany, has announced a price reduction of 27% for COVID-19 drug FabiFlu.

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients

Jun 21, 2020, at 01:23 pm

New Delhi/IBNS: Amid the massive spike in number of cases, India-based pharmaceutical company 'Glenmark Pharmaceuticals' has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients having mild to moderate COVID-19 symptoms.